<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916863</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-111-NRM</org_study_id>
    <secondary_id>LX4211.111</secondary_id>
    <nct_id>NCT01916863</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™ (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of LX4211 and the comparator drug
      canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy
      subjects in comparison to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in rate of glucose appearance after meal (RaO)</measure>
    <time_frame>Days 1, 8, 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of total glucose appearance (RaT)</measure>
    <time_frame>Days 1, 8, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Days 1, 8, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial glucose</measure>
    <time_frame>Days 1, 8, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin</measure>
    <time_frame>Days 1, 8, 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of LX4211</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg canagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LX4211 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 400 mg</intervention_name>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canagliflozin 300 mg</intervention_name>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 Placebo</intervention_name>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects ≥18 to ≤55 years of age

          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140
             mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm

          -  Body mass index (BMI) ≥18 and ≤35 kg/sq m

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
             within 7 days of dosing

          -  Use of any investigational agent or study treatment within 30 days of Day -1

          -  Use of any protein or antibody-based therapeutic agents within 3 months of Screening

          -  Prior exposure to LX4211 or canagliflozin

          -  Daily use of &gt;5 cigarettes or any tobacco products within 6 weeks prior to Screening
             and while participating in the study

          -  History of bariatric surgery or any other gastrointestinal surgery that may induce
             malabsorption

          -  History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI
             procedure for the purpose of weight loss which would slow gastric emptying

          -  History of any major surgery within 6 months prior to Screening

          -  History of any hypersensitivity to the inactive components of LX4211, inactive
             components of canagliflozin, acetaminophen oral solution or any inactive component of
             acetaminophen liquid preparation

          -  History of renal disease or significantly abnormal kidney function tests

          -  History of hepatic disease or significantly abnormal liver function tests

          -  History of any active infection within 30 days prior to Day -1

          -  History of alcohol or substance abuse within 2 years prior to Day 1

          -  History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1
             or HIV-2

          -  Donation or loss of &gt;500 mL of blood or blood product within 56 days of Day -1

          -  positive pregnancy test at Screening or Day -1

          -  Positive urine screen for drugs of abuse at Screening or Day -1

          -  Positive breath test for alcohol at Screening or Day -1

          -  Inability or difficulty swallowing whole tablets

          -  Unable or unwilling to communicate or cooperate with the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Strumph, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

